Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31094788 | 0.98 | ALDH1A1 (0.44) | ALDH1A1NPSR1TSHRL3MBTL1THRB | |
| SCHEMBL11704069 | 0.98 | ALDH1A1 (0.44) | ALDH1A1NPSR1TSHRL3MBTL1THRB | |
| SCHEMBL16424346 | 0.96 | ALDH1A1 (0.39) | ALDH1A1NPSR1TSHRL3MBTL1THRB | |
| SCHEMBL546205 | 0.93 | L3MBTL1 (0.41) | ALDH1A1NPSR1TSHRL3MBTL1MEN1 | |
| SCHEMBL9630324 | 0.85 | L3MBTL1 (0.50) | ALDH1A1TSHRL3MBTL1THRBATM | |
| SCHEMBL25471357 | 0.85 | SLC6A2 (0.44) | ALDH1A1TSHRL3MBTL1MEN1GAA | |
| SCHEMBL9762735 | 0.85 | ALDH1A1 (0.43) | ALDH1A1NPSR1TSHRL3MBTL1MEN1 | |
| SCHEMBL31724386 | 0.83 | ALDH1A1 (0.42) | ALDH1A1NPSR1TSHRL3MBTL1MEN1 | |
| SCHEMBL19815566 | 0.83 | CPN1 (0.42) | ALDH1A1NPSR1TSHRL3MBTL1ATM | |
| SCHEMBL20298656 | 0.82 | ALDH1A1 (0.42) | ALDH1A1NPSR1TSHRL3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4532484-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-119173509-A | ROCK inhibitors and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2023226965-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | ALDH1A1 2229/4885NPSR1 4247/4885TSHR 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.